Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome

Cura, 2009, Diagnostic and interventional radiology for Budd-Chiari syndrome, RadioGraphics, 29, 669, 10.1148/rg.293085056 Buckley, 2007, Imaging of Budd-Chiari syndrome, Eur Radiol, 17, 2071, 10.1007/s00330-006-0537-2 Valla, 2018, Budd-Chiari syndrome/hepatic venous outflow tract obstruction, Hepatol Int, 12, 168, 10.1007/s12072-017-9810-5 2016, EASL Clinical Practice Guidelines: vascular diseases of the liver, J Hepatol, 64, 179, 10.1016/j.jhep.2015.07.040 Cazals-Hatem, 2003, Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: a study in 17 explanted livers, Hepatol Baltim Md, 37, 510, 10.1053/jhep.2003.50076 Moucari, 2008, Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors, Gut, 57, 828, 10.1136/gut.2007.139477 Shin, 2004, Characteristic clinical features of hepatocellular carcinoma associated with Budd-Chiari syndrome: evidence of different carcinogenic process from hepatitis B virus-associated hepatocellular carcinoma, Eur J Gastroenterol Hepatol Mars, 16, 319, 10.1097/00042737-200403000-00012 Wang, 2013, Clinical and pathological features and surgical treatment of Budd-Chiari syndrome-associated hepatocellular carcinoma, Chin Med J (Engl), 126, 3632 Vilgrain, 2018, Benign and malignant hepatocellular lesions in patients with vascular liver diseases, Abdom Radiol N Y, 43, 1968, 10.1007/s00261-018-1502-7 Vilgrain, 1999, Hepatic nodules in Budd-Chiari syndrome: imaging features, Radiology, 210, 443, 10.1148/radiology.210.2.r99fe13443 Brancatelli, 2002, Benign regenerative nodules in Budd-Chiari syndrome and other vascular disorders of the liver: radiologic-pathologic and clinical correlation, Radiogr Rev Publ Radiol Soc N Am Inc Août, 22, 847 Maetani, 2002, Benign hepatic nodules in Budd-Chiari syndrome: radiologic-pathologic correlation with emphasis on the central scar, AJR Am J Roentgenol, 178, 869, 10.2214/ajr.178.4.1780869 Galle, 2018, EASL clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, 69, 182, 10.1016/j.jhep.2018.03.019 Heimbach, 2018, AASLD guidelines for the treatment of hepatocellular carcinoma: Heimbach et al, Hepatology, 67, 358, 10.1002/hep.29086 van Wettere, 2019, Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari, J Hepatol, 70, 1123, 10.1016/j.jhep.2019.01.009 Grazioli, 2005, Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study, Radiology, 236, 166, 10.1148/radiol.2361040338 Grazioli, 2012, Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis, Radiology, 262, 520, 10.1148/radiol.11101742 Zech, 2008, Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial, Invest Radiol, 43, 504, 10.1097/RLI.0b013e3181705cd1 Gupta, 2012, Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium, AJR Am J Roentgenol Juill, 199, 35, 10.2214/AJR.11.7757 Fujiwara, 2011, Ring-like enhancement of focal nodular hyperplasia with hepatobiliary-phase Gd-EOB-DTPA-enhanced magnetic resonance imaging: radiological-pathological correlation, Jpn J Radiol, 29, 739, 10.1007/s11604-011-0624-4 Yoneda, 2012, Hepatocyte transporter expression in FNH and FNH-like nodule: correlation with signal intensity on gadoxetic acid enhanced magnetic resonance images, Jpn J Radiol, 30, 499, 10.1007/s11604-012-0085-4 Ba-Ssalamah, 2015, Morphologic and molecular features of hepatocellular adenoma with gadoxetic acid-enhanced MR imaging, Radiology, 277, 104, 10.1148/radiol.2015142366 Tse, 2016, Qualitative and quantitative gadoxetic acid-enhanced MR imaging helps subtype hepatocellular adenomas, Radiology, 279, 118, 10.1148/radiol.2015142449 McInnes, 2015, Focal nodular hyperplasia and hepatocellular adenoma: accuracy of gadoxetic acid-enhanced MR imaging--a systematic review, Radiology, 277, 413, 10.1148/radiol.2015142986 Newerla, 2012, Multiple FNH-like lesions in a patient with chronic Budd-Chiari syndrome: Gd-EOB-Enhanced MRI and BR1 CEUS findings, Case Rep Radiol, 2012, 685486 Renzulli, 2011, Large regenerative nodules in a patient with Budd-Chiari syndrome after TIPS positioning while on the liver transplantation list diagnosed by Gd-EOB-DTPA MRI, Hepatobiliary Pancreat Dis Int, 10, 439, 10.1016/S1499-3872(11)60075-1 Roncalli, 2016, Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma, Clin Mol Hepatol, 22, 199, 10.3350/cmh.2016.0101 Brancatelli, 2007, Budd-Chiari syndrome: spectrum of imaging findings, AJR Am J Roentgenol, 188, W168, 10.2214/AJR.05.0168 Brancatelli, 2002, Large regenerative nodules in Budd-Chiari syndrome and other vascular disorders of the liver: CT and MR imaging findings with clinicopathologic correlation, AJR Am J Roentgenol, 178, 877, 10.2214/ajr.178.4.1780877 Neri, 2016, ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents, Eur Radiol, 26, 921, 10.1007/s00330-015-3900-3 Mamone, 2019, Budd-Chiari syndrome and hepatic regenerative nodules: magnetic resonance findings with emphasis of hepatobiliary phase, Eur J Radiol, 117, 15, 10.1016/j.ejrad.2019.05.015 Park, 2010, Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience, Korean J Radiol, 11, 433, 10.3348/kjr.2010.11.4.433 Khouri Chalouhi, 2019, Hepatobiliary phase in cirrhotic patients with different model for end-stage Liver disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine, Eur Radiol, 29, 3090, 10.1007/s00330-018-5884-2